H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on EDAP TMS to $16 from $13 and keeps a Buy rating on the shares following the appointment of Ryan Rhodes as CEO. With U.S. reimbursement at the highest level possible, the analyst is "confident that with a strong leader at the helm, EDAP is well poised for growth in 2023 and beyond."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDAP:
- EDAP TMS announces live procedure broadcast of Focal One HIFU
- EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
- EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
- EDAP TMS announces regulatory clearance of ExactVu Micro-Ultrasound in Japan
- EDAP TMS appoints Ryan Rhodes to succeed Marc Oczachowski as CEO